---
title: "Pre-market hot trades in US stocks: Kaival Brands Innovations up 7.99% in pre-market; Tenaya Therapeutics up 7.34% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269698700.md"
description: "Kaival Brands Innovations rose 7.99% in pre-market; Tenaya Therapeutics rose 7.34% in pre-market; Dongfang Culture rose 69.77% in pre-market; AMC Robotics rose 58.67% in pre-market; cbdMD rose 40.00% in pre-market"
datetime: "2025-12-15T09:52:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269698700.md)
  - [en](https://longbridge.com/en/news/269698700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269698700.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Kaival Brands Innovations up 7.99% in pre-market; Tenaya Therapeutics up 7.34% in pre-market

**Popular Pre-Market Trades in US Stocks**

Kaival Brands Innovations, up 7.99% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Tenaya Therapeutics is up 7.34% in pre-market. Based on recent key news:

1.  On December 12, Tenaya Therapeutics announced a public offering of 50 million units at a price of $1.20 per unit, raising $60 million. This move led to a pre-market drop of over 12% in the stock price. Source: MT Newswires

2.  On December 12, Tenaya Therapeutics reported positive mid-term data for its TN-401 gene therapy, showing a significant reduction in arrhythmia burden observed in patients with PKP2-related ARVC. This news drove the stock price up. Source: Reuters

3.  On December 12, Chardan Capital lowered the target price for Tenaya Therapeutics from $9 to $8, reflecting market concerns about its financial performance. Source: Chardan Capital. The biotechnology sector has been volatile recently and requires attention.

**Top Gainers in Pre-Market US Stocks**

Oriental Culture, up 69.77% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

AMC Robotics, up 58.67% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

cbdMD is up 40% in pre-market. Based on recent key news:

1.  On December 12, the U.S. President plans to change cannabis-related regulations through an executive order. Although this move will not legalize or decriminalize cannabis, it will make it easier for related businesses to sell cannabis products and promote new research on the effects of cannabis. As a CBD distributor, cbdMD's stock price rose as a result. Following the announcement, cbdMD's stock price increased by 96.51% in pre-market trading, with a trading volume exceeding 68 million shares, far surpassing the three-month daily average trading volume of 7.54 million shares. The policy changes in the cannabis industry have significant impacts

### Related Stocks

- [KAVL.US](https://longbridge.com/en/quote/KAVL.US.md)
- [TNYA.US](https://longbridge.com/en/quote/TNYA.US.md)

## Related News & Research

- [Fed's Hammack signals support for gradual rate-hike path](https://longbridge.com/en/news/305342093.md)
- [The S&P 500 is shrugging off Nvidia's selloff. Here's what's keeping the rest of the market afloat.](https://longbridge.com/en/news/305355417.md)
- [Nvidia options traders bank on longer-term stock recovery](https://longbridge.com/en/news/305359219.md)
- ['Not Yet,' Says Investor About SpaceX Stock](https://longbridge.com/en/news/305357492.md)
- [Cerebras (CBRS) vs. TSMC (TSM): Which Stock Has More Upside, According to Analysts?](https://longbridge.com/en/news/305260820.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**